Skip to content

Study · Randomized controlled trial · n = 16 · 2010

2 results

Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB

Biological psychiatry7 Nov 2009Cited by 686 (Europe PMC)

PMID19897177 (opens in a new tab)DOI10.1016/j.biopsych.2009.09.020 (opens in a new tab)PepBankPUB-19897177
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In male youth with autism spectrum disorders, oxytocin nasal spray improved emotion recognition performance compared with placebo.

    In plain wordsIn male youth with autism, oxytocin nasal spray improved emotion recognition more than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseReading the Mind in the Eyes Task performance
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    18 or 24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    In comparison with placebo, oxytocin administration improved performance on the Reading the Mind in the Eyes Task.
    1 context sentence
    Summary · context
    In a double-blind, randomized, placebo-controlled, crossover design, we administered oxytocin nasal spray (18 or 24 IU) or a placebo to 16 male youth aged 12 to 19 who were diagnosed with Autistic or Asperger's Disorder.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In male youth aged 12 to 15 with autism spectrum disorders given the lower dose, oxytocin nasal spray also improved emotion recognition performance compared with placebo.

    In plain wordsIn autistic boys aged 12 to 15 on the lower dose, oxytocin nasal spray also improved emotion recognition more than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseReading the Mind in the Eyes Task performance in younger participants, lower dose
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    lower dose (of 18 or 24 IU) · intranasalAs given in this study (human).

    Source sentences

    Summary
    This effect was also shown when analysis was restricted to the younger participants aged 12 to 15 who received the lower dose.
    1 context sentence
    Summary · context
    In a double-blind, randomized, placebo-controlled, crossover design, we administered oxytocin nasal spray (18 or 24 IU) or a placebo to 16 male youth aged 12 to 19 who were diagnosed with Autistic or Asperger's Disorder.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 4 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT03060031

Effects of Intranasal Oxytocin Administration on Social Influence Effects on Pain

University of Colorado, Bouldern = 5121 Jun 2017 to 1 Apr 2019

Pain

Trial pageClinicalTrials.govUpdated 25 Jun 2019
CompletedNot applicableNCT03081832

Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

University Hospital, Toulousen = 34Jan 2017 to Dec 2018

Prader-Willi Syndrome

Trial pageClinicalTrials.govUpdated 30 Jan 2019
CompletedNot applicableNCT03114371

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

University Hospital, Toulousen = 4028 Nov 2016 to 11 Jan 2019

Prader-Willi Syndrome

Trial pageClinicalTrials.govUpdated 12 Nov 2020
CompletedPhase 1Results postedNCT01834261

Brain Dynamics of Oxytocin

Stony Brook Universityn = 51Apr 2013 to May 2015

Brain Dynamics in Healthy Adults

Trial pageClinicalTrials.govUpdated 17 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.